COT FSA PBPK for Regulators Workshop Report 2021

Questions put forward for the discussion sessions- 2021

Last updated: 11 April 2024

22.             The below were the questions put forward for the discussion sessions.

Limitations / Ensuring fitness for purpose

  •  What are (if there are any), the limitations of using PBPK modelling in an agrochemical/pharmacological setting?
  • Can PBPK models fully replace animal testing, or are there some cases where animal studies may still be required?
  • Are there any circumstances where we can use simpler in silico compartmental models versus PBPK?

Potential applications

  •  Can PBPK models be used to provide relevant substances to benchmark against known human biomonitoring data?
  • Exploration into intracellular dosing.
  • Could PBPK modelling be used to convert estimates of external exposure into an estimate of internal exposure at the site where toxicity occurs to refine estimates of risk?
  •  PBPK modelling provides a way to incorporate kinetics into consideration in animal-free, in vitro based safety/risk assessment and to relative in vitro toxicity assay findings to human safe exposure estimates.
  • Can PBPK models lower the reliance on default uncertainty factors, and would it reduce this uncertainty?

Validation for regulatory application

  •  Are there any harmonised guidelines available for regulators?
  • Have there been any cases where there has been a human PBPK model developed without human data? If so, how was the model validated (if at all)?
  •  What are some of the hurdles to PBPK modelling being used more widely by scientists, and accepted by regulators?

Duties as regulators

  •  What aspects of the model do regulators have to check before it can be used in risk assessment?
  •  Are regulators expected to use PBPK models (for example, to double-check calculations, to examine the source code) or can regulators just take simulation results at face value?
  •    How could PBPK modelling be used more extensively in food safety assessment?
  •   Is the integration of PBPK models into current human health assessment methodologies a risk worth embracing?